Tuesday, Pfizer Inc (NYSE:PFE) released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD). Among US adults 18 to 49 years, 9.5% have a chronic condition that puts them at risk of severe RSV disease, and this percentage rises to 24.3% among persons 50 to 64 years of age. However, no RSV vaccines have been approved for use in adults 18 to 59.  The MONeT study achieved its co-primary immunogenicity endpoints and primary safety ...